

Press release
Lund 27 MAR 2024

ChemoTech secures order from the largest European state-of-the-art equine (horse) clinic

Scandinavian ChemoTech's Animal Care is delighted to confirm the receipt of an order of €48k from Europe's foremost equine clinic, EquiTom, Lummen in Belgium, distinguished for its pioneering advancements in equine healthcare.

With a stellar reputation and being the largest, most innovative equine clinic in Europe with a hospitalisation capacity of more than 150 horses, receiving clients from more than 70 countries, this clinic stands as a beacon of excellence in the field of equine medicine.

Their decision to invest in the vetIQure™ system was made after a successful training and introduction including treating three patients with sarcoids (a common tumour amongst horses). This clearly demonstrates the superiority of our technology, TSE (Tumour Specific Electroporation™), compared to older destructive therapies that are still prevalent in current treatments.

"After successfully treating three patients over the past two weeks, I can clearly see the benefit and added value of the TSE therapy compared to what we have access to today for treating sarcoids. The integration of vetIQure™ TSE technology will enhance the overall experience for both our clinic and our patients, thereby increasing the value proposition." says Liesbeth Haegeman, Resident in Equine Surgery ECVS at EquiTom

"Securing a commercial agreement with EquiTom marks a major milestone for us as we expand into Europe. Our goal is to lead in providing cutting-edge healthcare solutions for horses and companion animals dealing with cancer and sarcoids." says Mohan Frick, CEO of Scandinavian ChemoTech.

The integration of vetIQure™ into EquiTom's operations showcases its commitment to innovative and excellent equine healthcare. With our technology, clinicians gain a powerful, non-destructive tool for treating tumours, most often without general anesthesia, using only standing sedation.

About EquiTom Equine Clinic

Equitom, founded in 2001 by Dr. Tom Mariën, has evolved over the years into one of the leading Equine Hospitals in the world. Situated in the centre of Belgium, the hospital is very accessible to clients coming from Belgium and the surrounding countries. Equitom has an exceptional and international reputation receiving clients from more than 70 countries. EquiTom is the Equine hospital with the largest visibility on social media worldwide and is internationally known as 'the hospital of the last hope'. Besides a renowned surgical department, the hospital has a 'state of the art' diagnostic imaging and orthopaedic department with an in-house rehabilitation service. In 2023 EquiTom became the largest and most innovative equine clinic in Europe with a hospitalisation capacity of more than 150 horses.

The Europe veterinarian market size

According to a report by Grand View Research published in 2022¹, the Europe veterinarians market size was valued at USD 17.66 billion in 2022 and is expected to grow at a compound annual growth rate (CAGR) of 7.56% from 2023 to 2030. The horse population in Europe is estimated to be between 6 to 7 million.²

¹ [grandviewresearch.com/](https://www.grandviewresearch.com/)

² Gitnux Marketdata Report 2024 – Must-know Equestrian Industry Statistics

For further information please contact:

Mohan Frick, CEO

Phone: +46 (0)10-218 93 00

E-mail: ir@chemotech.se

Certified Adviser: Redeye AB, Phone: +46 (0)8 - 121 576 90

E-mail: certifiedadviser@redeye.se

This disclosure contains information that ChemoTech is obliged to make public pursuant to the EU Market Abuse Regulation (EU nr 596/2014). The information was submitted for publication, through the agency of the contact person, on 27-03-2024 14:45 CET.

Scandinavian ChemoTech AB (publ)

ChemoTech is a Swedish medical technology company based in Lund that has developed a patented technology platform to offer cancer patients access to a new treatment alternative, Tumour Specific Electroporation™ (TSE), available for treatment of both humans and animals. There are a large number of cancer patients whose tumours for various reasons cannot be treated by conventional methods but where TSE can be a solution. Therefore, the company continuously evaluates new opportunities and areas of application for the technology. ChemoTech's shares (CMOTEC B) are listed on Nasdaq First North Growth Market in Stockholm and Redeye AB is the company's Certified Adviser. Read more at: www.chemotech.se.